Definitive Contract HHSN271201100013C

Award Date 8/17/11
Potential Completion Date 6/30/22
Potential Value $54M
Contracting Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Albany, NY 12212, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,349,436.46 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc., doing business as AMRI. The contract is part of NINDS's Medicinal Chemistry Support Program for Therapeutic Development, which focuses on early-stage drug discovery research. The contract provides for exploratory chemistry and other pharmaceutical research and development services to support NINDS's scientific initiatives,...
This is a $3,453,835.19 delivery order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc., doing business as Amri, a for-profit manufacturer. The contract is for the Medicinal Chemistry Support Program for Therapeutic Development, which provides chemistry, manufacturing, and controls development; exploratory chemistry; hit-to-lead chemistry;...
The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded a $3,173,498.83 cost-plus-fixed-fee Delivery Order contract to Curia Global Inc., doing business as Amri, for Exploratory Chemistry services under the Medicinal Chemistry Support Program for Therapeutic Development. The contract has a completion date of February 1, 2026 and does not have a small business set-aside designation. Curia, a global contract...
This is a delivery order contract awarded by the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc., doing business as Amri, for the Medicinal Chemistry Support Program for Therapeutic Development. The contract, with a potential value of $4,042,434.33, provides chemistry, manufacturing, and controls development; exploratory chemistry; hit-to-lead chemistry; absorption/distribution/metabolism/excretion testing; process...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to Curia Global Inc. (doing business as Amri) for $815,714.07. The contract is for medicinal chemistry services to support the "ALDRICH (UNIV. OF FLORIDA) - EXPLORATORY CHEMISTRY-ADMET ONLY - MCSP" project, which is part of NINDS's Medicinal Chemistry Support Program for therapeutic development. Curia, a...
This is a delivery order awarded to Curia Global Inc., doing business as Amri, by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke. The $662,706.10 cost-plus-fixed-fee contract is to provide chemistry and absorption/distribution/metabolism/excretion (ADMET) services in support of the Medicinal Chemistry Support Program (MCSP) and other NIH initiatives related to neurology, infectious diseases, and...
This is a delivery order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to Curia Global Inc., doing business as Amri, for the NIH Blueprint Neurotherapeutics Network Medicinal Chemistry Support Program (MCSP). The $270,144.53 cost-plus-fixed-fee contract is to provide medicinal chemistry support services for therapeutic development, including services such as exploratory chemistry,...
This is a federal contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to Curia Global Inc., doing business as Amri, a leading global contract development and manufacturing organization (CDMO). The $2,873,042.91 contract is for the Medicinal Chemistry Support Program for Therapeutic Development, under which Curia will provide a range of chemistry, manufacturing, and controls development...
This is a federal contract award to Curia Global Inc., doing business as Amri, by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke. The contract, valued at $3,360,769.23, is for the Medicinal Chemistry Support Program for Therapeutic Development (MCSP-EC), which involves exploratory chemistry services. The contract has a completion date of November 13, 2025 and was awarded on May 6, 2022. Curia Global is a...
This federal contract award, valued at $2,592,564.37, was issued by the National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc. (doing business as Amri), a leading global contract development and manufacturing organization (CDMO). The award is for a Delivery Order under the Biomedical Prototype Network - Medicinal Chemistry Support Program for Therapeutic Development (BPN-MCSP-HIT) to support chemistry-related services, including hit-to-lead chemistry, for the Martin...

This is a $53,718,942.02 Cost Plus Fixed Fee definitive contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency within the National Institutes of Health (NIH), to Curia Global Inc. (doing business as Amri). The contract is for the Medicinal Chemistry for Neurotherapeutics Program (MCNP), which supports the development of small molecule drug candidates for neurological disorders. Curia, a global contract development and manufacturing organization (CDMO), will provide a range of services including medicinal chemistry, chemical development, analytical testing, formulation development, and cGMP manufacturing. The contract has an ultimate completion date of June 30, 2022 and does not have a set-aside designation. Curia has extensive experience supporting various NIH institutes and other federal agencies through prime and subcontract awards, focusing on therapeutic development initiatives in areas such as neurology, infectious diseases, and substance abuse.

Generated 9/28/24, 9:23 AM